Status:
COMPLETED
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Lead Sponsor:
Seagen Inc.
Conditions:
Hodgkin Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stag...
Eligibility Criteria
Inclusion
- Histopathological diagnosis of classical Hodgkin lymphoma
- Failed standard front-line therapy
- Measurable disease of at least 1.5 cm as documented by radiographic technique
- Eastern Cooperative Oncology Group performance status less than or equal to 2
Exclusion
- Received prior salvage therapy, including radiotherapy
- Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug
- Concurrent use of other investigational agents
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2018
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT01874054
Start Date
June 1 2013
End Date
February 20 2018
Last Update
February 12 2019
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Pacific Hematology Oncology Associates
San Francisco, California, United States, 94115
3
Stanford Cancer Center
Stanford, California, United States, 94305
4
Oncology Institute of Hope & Innovation, The
Whittier, California, United States, 90603